Viatris (VTRS): financials, SEC filings and peers
Viatris (VTRS) is a pharmaceuticals company in the Health Care sector of the S&P 500, headquartered in Pittsburgh, Pennsylvania.
It was founded in 1961 and joined the S&P 500 on April 23, 2004.
Its fiscal year ends in December, and its shares trade on the Nasdaq.
In its SEC filings it is classified as “Pharmaceutical Preparations”.
Viatris at a glance
- Revenue (12 months)
- $14.7B
- Revenue growth
- +4.4%
- Operating margin
- -0.6%
- Net income (12 months)
- —
- Free cash flow (12 months)
- $2.0B
- Cash
- $887M
- Debt
- $13.4B
- Diluted EPS (12 months)
- $-0.36
Twelve months to June 30, 2026, from the 10-Q filed August 6, 2026.
Latest twelve months
Over the twelve months to June 30, 2026, Viatris reported revenue of $14.7 billion, about the same as a year earlier (+4.4%).
Its operating margin was -0.6%, up 17.8 percentage points from a year earlier: for every $100 of sales, about $0 was left as operating profit.
Operating cash flow was $2.3 billion and capital spending $376 million, leaving free cash flow of $2.0 billion (13.3% of revenue).
At the end of the period it held $887 million in cash and $13.4 billion in debt, a net debt position of $12.5 billion.
Five-year trend
- Revenue went from $11.9 billion in fiscal 2020 to $14.3 billion in fiscal 2025, about 3.7% a year.
- Operating margin narrowed from -1.8% to -18.6% over the same years.
- Free cash flow was positive in each of the last 6 fiscal years.
- Viatris reported a net loss in 4 of the last 6 fiscal years.
| Fiscal year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $17.9B | $16.3B | $15.4B | $14.7B | $14.3B |
| Revenue growth | 49.7% | -9.1% | -5.1% | -4.5% | -3.0% |
| Operating margin | -0.2% | 9.9% | 5.0% | 0.1% | -18.6% |
| Net income | −$1.3B | $2.1B | $55M | −$634M | −$3.5B |
| Free cash flow | $2.6B | $2.6B | $2.5B | $2.0B | $1.9B |
| Diluted EPS | $-1.05 | $1.71 | $0.05 | $-0.53 | $-3.00 |
Fiscal years as reported in Viatris’s 10-K filings. Free cash flow is operating cash flow minus capital spending.
Recent SEC filings
- 10-Q filed August 6, 2026 — quarterly report
- 8-K filed August 6, 2026 — Earnings results; Other event
- 8-K filed July 1, 2026 — Material agreement; New debt obligation
- 8-K filed June 18, 2026 — Material agreement; New debt obligation
- 8-K filed June 15, 2026 — Other event
- 8-K filed May 15, 2026 — Shareholder vote results
- 10-Q filed May 7, 2026 — quarterly report
- 8-K filed May 7, 2026 — Earnings results; Other event
Companies like Viatris
Other S&P 500 companies in Pharmaceuticals:
- BMYBristol Myers SquibbNew York City, New York
- JNJJohnson & JohnsonNew Brunswick, New Jersey
- LLYLilly (Eli)Indianapolis, Indiana
- MRKMerck & Co.Kenilworth, New Jersey
- PFEPfizerNew York City, New York
- ZTSZoetisParsippany, New Jersey
More from Health Care
Questions about Viatris
Is Viatris's revenue growing?
Yes. Revenue for the twelve months to June 30, 2026 was $14.7 billion, up 4.4% from a year earlier, according to its SEC filings.
Does Viatris have more cash or more debt?
At June 30, 2026 it had $887 million in cash and $13.4 billion in debt, so more debt than cash.
When did Viatris last file financial results?
Its latest quarterly report (10-Q) was filed with the SEC on August 6, 2026.
Which companies are similar to Viatris?
In the S&P 500, Viatris is grouped in Pharmaceuticals within the Health Care sector. Bristol Myers Squibb (BMY), Johnson & Johnson (JNJ), Lilly (Eli) (LLY), Merck & Co. (MRK), Pfizer (PFE) are in the same group.
Understand the numbers
Source: Viatris’s filings with the U.S. Securities and Exchange Commission (EDGAR), retrieved September 27, 2026. Figures are as reported by the company and may be restated. This page is for information only and is not financial advice.